Author

I. Puzanov

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

G. Chatta· 3 shared A. Tracz· 2 shared D. G. Tang· 2 shared M. Long· 2 shared X. Liu· 2 shared A. Dommer· 1 shared A. L. Kasinski· 1 shared A. M. Abdelaal· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

G. Chatta

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises

W. Li, Y. Wang, X. Liu, S. Wu, M. Wang, S. G. Turowski, J. A. Spernyak, A. Tracz, A. M. Abdelaal, K. Sudarshan, I. Puzanov, G. Chatta, A. L. Kasinski, D. G. Tang

This study evaluates folate-conjugated miR-34a as a potential prostate cancer therapeutic, finding limited efficacy due to low FOLR1 expression in prostate cancer cells.

bioRxiv · Nov 25, 2023 · PreprintCancer Biology

Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells

J. S. Kirk, J. Wang, A. Tracz, M. Long, S. R. Rosario, Y. Ji, R. Kumar, X. Liu, P. K. Singh, I. Puzanov, G. Chatta, Q. Cheng, J. Huang, J. L. Wrana, J. Lovell, , D. G. Tang

The paper uses multi-omics single-cell data to define the epigenetic basis of castration-resistant prostate luminal cells in mice and identifies key molecular pathways involved.

bioRxiv · Mar 3, 2023Cancer Biology

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells

Y. Shi, M. Dolan, M. Mastri, A. McKenery, J. W. Hill, A. Dommer, S. Benzekry, M. Long, S. Abrams, I. Puzanov, J. M. L. Ebos

This study identifies an IFN-stimulated secretory program in PD-L1-resistant tumors that promotes immune evasion and shows that targeting this program can inhibit tumor growth.

bioRxiv · Jul 1, 2021 · PreprintCancer Biology

A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors

T. Yamauchi, T. Hoki, T. Oba, V. Jain, H. Chen, K. Attwood, S. Battaglia, S. George, G. Chatta, I. Puzanov, C. Morrison, K. Odunsi, B. H. Segal, G. K. Dy, M. S. Ernstoff, F. Ito

The paper identifies CX3CR1 expression on circulating CD8+ T cells as a biomarker predicting response to immune checkpoint inhibitor therapy in NSCLC patients.

bioRxiv · Jun 13, 2020Immunology